A Phase 3 Trial of Brepocitinib in Dermatomyositis.

Vleugels RA, Paik JJ, Bauer Ventura I, Mangold AR, Gandiga PC, Haemel A, Chinoy H, Hussain YM, Sivakumar K, Griger Z, Lee EB, Bozan F, Hsu CY, Femia A, Dimachkie MM, Min MS, Mozaffar T, Charles-Schoeman C, Fernandez DR, Onajin O, Campanilho-Marques R, Marder G, Ernste F, Schiopu E, Sluzevich J, Pearson D, Lindsey S, Luggen M, Bubb MR, Boh E, Maganti R, Heinlen L, Shaw KS, Cascino MD, Mudd PN Jr, Vencovsky J, Fernandez AP, Fiorentino D, Christopher-Stine L, Werth VP, Aggarwal R, VALOR Investigators

Open source

DOI: 10.1056/nejmoa2503531
Published: 2026 May 14
Container: The New England journal of medicine
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa2503531,
  title = {A Phase 3 Trial of Brepocitinib in Dermatomyositis.},
  author = {Vleugels RA and Paik JJ and Bauer Ventura I and Mangold AR and Gandiga PC and Haemel A and Chinoy H and Hussain YM and Sivakumar K and Griger Z and Lee EB and Bozan F and Hsu CY and Femia A and Dimachkie MM and Min MS and Mozaffar T and Charles-Schoeman C and Fernandez DR and Onajin O and Campanilho-Marques R and Marder G and Ernste F and Schiopu E and Sluzevich J and Pearson D and Lindsey S and Luggen M and Bubb MR and Boh E and Maganti R and Heinlen L and Shaw KS and Cascino MD and Mudd PN Jr and Vencovsky J and Fernandez AP and Fiorentino D and Christopher-Stine L and Werth VP and Aggarwal R and VALOR Investigators},
  year = {2026},
  journal = {The New England journal of medicine},
  doi = {10.1056/nejmoa2503531},
  url = {https://doi.org/10.1056/nejmoa2503531}
}

RIS

TY  - JOUR
TI  - A Phase 3 Trial of Brepocitinib in Dermatomyositis.
AU  - Vleugels RA
AU  - Paik JJ
AU  - Bauer Ventura I
AU  - Mangold AR
AU  - Gandiga PC
AU  - Haemel A
AU  - Chinoy H
AU  - Hussain YM
AU  - Sivakumar K
AU  - Griger Z
AU  - Lee EB
AU  - Bozan F
AU  - Hsu CY
AU  - Femia A
AU  - Dimachkie MM
AU  - Min MS
AU  - Mozaffar T
AU  - Charles-Schoeman C
AU  - Fernandez DR
AU  - Onajin O
AU  - Campanilho-Marques R
AU  - Marder G
AU  - Ernste F
AU  - Schiopu E
AU  - Sluzevich J
AU  - Pearson D
AU  - Lindsey S
AU  - Luggen M
AU  - Bubb MR
AU  - Boh E
AU  - Maganti R
AU  - Heinlen L
AU  - Shaw KS
AU  - Cascino MD
AU  - Mudd PN Jr
AU  - Vencovsky J
AU  - Fernandez AP
AU  - Fiorentino D
AU  - Christopher-Stine L
AU  - Werth VP
AU  - Aggarwal R
AU  - VALOR Investigators
PY  - 2026
JO  - The New England journal of medicine
DO  - 10.1056/nejmoa2503531
UR  - https://doi.org/10.1056/nejmoa2503531
ER  -

APA

RA, V., JJ, P., I, B. V., AR, M., PC, G., A, H., H, C., YM, H., K, S., Z, G., EB, L., F, B., CY, H., A, F., MM, D., MS, M., T, M., C, C., DR, F., O, O., R, C., G, M., F, E., E, S., J, S., D, P., S, L., M, L., MR, B., E, B., R, M., L, H., KS, S., MD, C., Jr, M. P., J, V., AP, F., D, F., L, C., VP, W., R, A., & Investigators, V. (2026). A Phase 3 Trial of Brepocitinib in Dermatomyositis.. The New England journal of medicine. https://doi.org/10.1056/nejmoa2503531

Source records

pubmed · retrieved 2026-09-26T10:24:33.084Z